If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q-Bot: £3.5 million investment to drive expansion

13 Sep 2023 07:00

RNS Number : 2253M
NetScientific PLC
13 September 2023
 

Reach: For release at 07.00, 13 September 2023

 

 

 

 

NetScientific plc

("NetScientific" or the "Company")

Q-Bot secures £3.5 million of investment to drive UK, Europe, and USA expansion

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that portfolio company Q-Bot has successfully closed a £3.5 million investment program ("Fundraising").

The Fundraising was led by the Company's wholly owned venture capital and corporate finance firm, EMV Capital, syndicated from a cohort of private investors and family offices. The new funding will support Q-Bot's growth in its principal UK market and expansion into Europe and the USA.

Following completion of the Fundraising, the total equity holding of NetScientific in Q-Bot is diluted to 15.3% (on a fully diluted basis), which equates to a post-investment fair value of £4.1 million, an increase of 9.2% from the £3.8 million reported as at 31 December 2022. In addition, following the introduction of investors to Q-Bot by EMV Capital, the NetScientific capital under advisory with Q-Bot is 30.7% of the fully diluted share capital. 

Alongside the fundraising, Q-Bot has also announced the appointment of John Kennedy as its new CEO following his joining Q-Bot in late 2022. John has extensive experience as CFO and CEO in growth businesses ranging from start-ups to publicly listed companies in technology and financial services.

Using AI and robotics, Q-Bot's insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. A remotely operated robotic device applies a continuous layer of spray-foam insulation to the underside of the floor, resulting in a reduction in heat loss through the floor and a barrier to cold air draughts.

Q-Bot's advanced insulation is installed in over 200 homes every month, with revenues increasing by 60% over the past 12 months. In the UK, the Directors understand that Q-Bot's high performance retrofit insulation has a target market of 8 to 12 million homes that have suspended floors and which are hard to treat using traditional forms of insulation. 

Lord Callanan, the UK Energy Minister with responsibility for Energy Efficiency and Green Finance, recently visited Q-Bot's new head office and retrofit research centre in London. During his visit, Lord Callanan praised Q-Bot's cutting-edge work and the contribution that Q-Bot was making to improve the energy efficiency of homes across the UK and in reducing carbon emissions, a vital component in the journey towards Net Zero.

John Kennedy, CEO of Q-Bot, said:

"This investment is a strong endorsement of our work and recognition of the market opportunity that exists in the UK and overseas. Our customers, from private individuals to energy suppliers and providers of social housing are assured by the comprehensive and professional approach that we take towards insulating homes whilst leveraging use of state-of-the-art robotics and AI."

Dr Ilian Iliev, CEO of NetScientific and Investment Director of Q-Bot, commented:

"We are pleased to see Q-Bot close out this important fundraising. The company continues to make strong progress in scaling sales with its innovative use of robotics and artificial intelligence in the Construction Technology industry, and in particular in the retrofit home insulation market. We look forward to seeing its continued success as it scales beyond the UK market, with a focus on market entry in the US and EU."

-ends-

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

About Q-Bot

Q-Bot, founded in 2012 by Tom Lipinski and Professor Peter Childs FREng, is a provider to the UK Government's Green Homes Local Authority Delivery Scheme, the Social Housing Decarbonisation Fund, Great British Insulation Scheme and Home Upgrade Grant. 

Q-Bot's floor insulation is installed in over 200 homes every month and to date the company has installed over 4,000 properties across the UK and Europe. The company works with over 50 registered social housing providers, energy companies such as E.ON and British Gas, as well as a network of accredited installers and property agents.

An average-sized UK household, insulated by Q-Bot, could typically save c.£850 per year in an electrically-heated home, and c.£270 a year in a gas-heated home. Studies show that the Q-Bot system reduces heat loss through the floor by 77% and cold draughts by 1/3 for the whole house. With retrofitting existing buildings seen as essential for the UK to reach Net Zero, a household using Q-Bot's solution can cut its annual CO₂ emissions by an average 700 kg.

Q-Bot's work has received grant support from the UK Government and Innovate UK, and it has won numerous awards, including the CIBSE Building Performance Award and the Queen's Award for Enterprise (Innovation). 

www.q-bot.co

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABRGDCCBBDGXD
Date   Source Headline
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.